Andrew King, Ph.D., is a distinguished biochemist and biotech leader with over 20 years of experience in drug discovery and development. He earned his Ph.D. in Molecular Biology from Stanford University, where his dissertation on targeted protein degradation garnered early acclaim, leading to a prestigious postdoctoral fellowship at the Broad Institute of MIT and Harvard. King's career began at Genentech, where he rose to Director of Oncology Research, spearheading projects that advanced three novel therapeutics into Phase II clinical trials. His work has resulted in over 50 peer-reviewed publications in top journals such as Nature Biotechnology and Cell, along with 12 issued patents on proprietary delivery platforms for nucleic acid therapies. Throughout his tenure at leading firms like Pfizer and Moderna, King demonstrated exceptional prowess in translating basic science into viable pipelines, notably contributing to mRNA-based platforms during the COVID-19 response and earning the Biotechnology Innovation Organization's Trailblazer Award in 2020. He co-founded a venture-backed startup focused on AI-driven small molecule design, which was acquired by a major pharmaceutical company, solidifying his reputation as a visionary in precision medicine. As President of Research and Development at JADE BIOSCIENCES INC., Dr. King oversees a robust pipeline of next-generation therapies targeting neurodegenerative diseases and rare genetic disorders. Under his leadership, the company has achieved key milestones, including FDA clearance for its lead IND and strategic partnerships with global pharma giants. King's strategic vision emphasizes integrating computational biology with experimental validation to accelerate innovation, positioning JADE at the forefront of transformative bioscience solutions.